Journal
EUROPACE
Volume 17, Issue 8, Pages 1294-1299Publisher
OXFORD UNIV PRESS
DOI: 10.1093/europace/euv255
Keywords
Ventricular tachycardia; Antiarrhythmic drugs; Catheter ablation; Implantable cardioverter-defibrillator; EHRA survey; EP Wire
Categories
Ask authors/readers for more resources
The purpose of this European Heart Rhythm Association (EHRA) survey was to assess clinical practice in the management of ventricular tachycardia (VT). The data are based on an electronic questionnaire sent to the members of the EHRA Research Network. Responses were received from 31 centres in 16 countries. The results of the survey show that the management of VT is in general in accordance with guidelines. Antiarrhythmic drugs are still frequently used for VT treatment. In patients at high risk of sudden cardiac death, an implantable cardioverter-defibrillator is routinely recommended, while the treatment options vary for patients with moderate or low risk. A discreet attitude is adopted for catheter ablation in high-risk patients as demonstrated by a relatively low rate of catheter ablation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available